1. Home
  2. CYTH vs XLO Comparison

CYTH vs XLO Comparison

Compare CYTH & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • XLO
  • Stock Information
  • Founded
  • CYTH 1990
  • XLO 2016
  • Country
  • CYTH United States
  • XLO United States
  • Employees
  • CYTH N/A
  • XLO N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYTH Health Care
  • XLO Health Care
  • Exchange
  • CYTH Nasdaq
  • XLO Nasdaq
  • Market Cap
  • CYTH 35.5M
  • XLO 36.2M
  • IPO Year
  • CYTH N/A
  • XLO 2021
  • Fundamental
  • Price
  • CYTH $1.15
  • XLO $1.01
  • Analyst Decision
  • CYTH Strong Buy
  • XLO
  • Analyst Count
  • CYTH 3
  • XLO 0
  • Target Price
  • CYTH $3.20
  • XLO N/A
  • AVG Volume (30 Days)
  • CYTH 42.5K
  • XLO 108.5K
  • Earning Date
  • CYTH 08-12-2024
  • XLO 08-12-2024
  • Dividend Yield
  • CYTH N/A
  • XLO N/A
  • EPS Growth
  • CYTH N/A
  • XLO N/A
  • EPS
  • CYTH N/A
  • XLO N/A
  • Revenue
  • CYTH $1,126,444.00
  • XLO N/A
  • Revenue This Year
  • CYTH $28.30
  • XLO N/A
  • Revenue Next Year
  • CYTH $14.19
  • XLO $150.00
  • P/E Ratio
  • CYTH N/A
  • XLO N/A
  • Revenue Growth
  • CYTH N/A
  • XLO N/A
  • 52 Week Low
  • CYTH $0.89
  • XLO $0.49
  • 52 Week High
  • CYTH $2.12
  • XLO $2.94
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 40.45
  • XLO 53.93
  • Support Level
  • CYTH $1.12
  • XLO $0.92
  • Resistance Level
  • CYTH $1.34
  • XLO $0.97
  • Average True Range (ATR)
  • CYTH 0.08
  • XLO 0.06
  • MACD
  • CYTH -0.01
  • XLO 0.01
  • Stochastic Oscillator
  • CYTH 10.71
  • XLO 88.24

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Share on Social Networks: